AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘s stock had its “outperform” rating reaffirmed by equities research analysts at FBR & Co in a report issued on Saturday. They presently have a $3.00 price objective on the biopharmaceutical company’s stock. FBR & Co’s target price would indicate a potential upside of 417.15% from the company’s current price.
AVEO Pharmaceuticals (NASDAQ:AVEO) traded down 1.6780% during mid-day trading on Friday, reaching $0.5801. The company’s stock had a trading volume of 469,257 shares. The company’s market cap is $44.01 million. The stock’s 50 day moving average is $0.72 and its 200 day moving average is $0.68. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $1.15.
In other AVEO Pharmaceuticals news, major shareholder Equity Opportunities Iv Growth purchased 6,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 28th. The stock was bought at an average cost of $0.50 per share, with a total value of $3,000,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 5.10% of the company’s stock.
Several hedge funds have recently modified their holdings of AVEO. Renaissance Technologies LLC increased its stake in shares of AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock worth $1,482,000 after buying an additional 148,500 shares during the last quarter. Sarissa Capital Management LP purchased a new stake in AVEO Pharmaceuticals during the fourth quarter worth about $917,000. New Leaf Venture Partners L.L.C. purchased a new stake in AVEO Pharmaceuticals during the fourth quarter worth about $1,399,000. Finally, Perceptive Advisors LLC purchased a new stake in AVEO Pharmaceuticals during the fourth quarter worth about $1,678,000. 37.94% of the stock is owned by institutional investors.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.